To increase awareness of the availability of the OPRA™ Implant System among specialists and patients, Integrum launches the “Find a Center” campaign.
Despite more than 30 years of research, development, and excellent clinical outcomes, many amputees and specialists around the world are still unaware of the advantages and availability of treatment with the OPRA™ Implant System. Integrum is therefore now launching the “Find a Center” campaign which will show how broadly established the OPRA™ network is. Today, there are more than 30 centers around the world helping patients to lead more active and productive lives. Please see the map below to see the global availability of the OPRA™ Implant System.
Says Maria Lopez, CEO at Integrum “We are very pleased that we have been able to increase our network in these challenging times, and offer even more patients a dramatically improved quality of life”.
For further information, please contact:
Maria Lopez, CEO
Cell. +46 (0) 708-46 10 69
Email: maria.lopez@integrum.se
Certified Adviser:
Erik Penser Bank AB
Tel. +46 (0) 8 463 8000
Email: certifiedadviser@penser.se
Integrum AB is a publicly-traded company (INTEG B: Nasdaq First North exchange) based outside of Gothenburg, Sweden, with a USsubsidiary in San Francisco, CA. Since1990 osseointegration, the science behind the OPRA™ Implant System has been helping individuals with amputations towards an improved quality of life. Thorough surgical experience gained over almost three decades from 500 surgeries in 14countries has led to the development of Integrum’s system for bone-anchored prosthetics –a beneficial alternative to the traditionally used socket prosthesis. Integrum’s OPRA™ Implant System was approved by the US Food and Drug Administration (FDA) in 2015 for use in the US under a Humanitarian Use Device (HUD) designation,which was reviewed through the Humanitarian Device Exemption (HDE) pathway, which limited the level of marketing and sales activities. In December 2020, Integrum successfully completedthe most stringent medical device regulatory procedure in the world, and based on the solid scientific data submitted, was granted a PMA by the FDA for the OPRATM Implant System, which is the only technology approvedfor above knee, bone-anchored prostheticsin the U.S.More information on the company and its innovative solutions for amputees can be found at www.integrum.se
